Modality
Nanobody
MOA
PD-1i
Target
MET
Pathway
RAS/MAPK
GAEndometrial Ca
Development Pipeline
Preclinical
Apr 2019
→ Aug 2030
PreclinicalCurrent
NCT07681221
244 pts·Endometrial Ca
2019-04→2030-08·Terminated
NCT03166281
2,545 pts·Endometrial Ca
2024-09→TBD·Terminated
2,789 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-174.4y awayInterim· Endometrial Ca
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Termina…
Preclinical
Termina…
Catalysts
Interim
2030-08-17 · 4.4y away
Endometrial Ca
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07681221 | Preclinical | Endometrial Ca | Terminated | 244 | HbA1c |
| NCT03166281 | Preclinical | Endometrial Ca | Terminated | 2545 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| RAP-2478 | Rapport Ther | Phase 3 | MET | |
| Mavuzasiran | Protagonist | Phase 3 | MET |